Business Context and Reporting Period
This Form 8-K is filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on February 5, 2018, reporting events occurring on January 31, 2018, and February 2, 2018. The company is an emerging growth company focused on developing clinical product candidates for cancer, pathological fibrosis, and heart failure. The filing coincides with the commencement of a public offering of up to 7.0 million shares of common stock.
Key Financial Metrics
The filing provides preliminary unaudited financial estimates as of December 31, 2017, while final audited results remain pending.
- Cash and Cash Equivalents: $47.4 million (as of December 31, 2017).
- Revenue, Profit, and Margins: The filing text does not provide clear values for revenue, net income, operating margins, or cash flow for the fiscal year ended December 31, 2017.
- Debt and Liquidity: No specific debt figures are disclosed in this text; liquidity is indicated by the $47.4 million cash balance.
Material Changes and Executive Compensation
On January 31, 2018, the Compensation Committee approved 2017 performance bonuses and 2018 compensation packages for executive officers.
| Executive Officer | 2017 Bonus | 2018 Base Salary | 2018 Bonus Target | Stock Options Granted |
|---|---|---|---|---|
| William S. Marshall, Ph.D. (CEO) | $180,000 | $490,000 | 50% | 245,000 shares |
| Jason A. Leverone (CFO) | $88,200 | $340,000 | 35% | 75,000 shares |
| Adam S. Levy (CBO) | $108,000 | $345,000 | 40% | 80,000 shares |
| Paul D. Rubin, M.D. (EVP R&D) | $142,200 | $410,000 | 40% | 85,000 shares |
Stock options were granted at an exercise price of $7.50 per share, vesting over four years with accelerated vesting provisions upon change of control.
Outlook, Risks, and Unusual Items
Capital Raise: The company commenced a public offering of up to 7.0 million shares of common stock on February 5, 2018. Final financial statements for the fiscal year ended December 31, 2017, will not be available until after this offering is consummated.
Clinical Developments: On February 2, 2018, the company announced new data from the Phase 1 clinical trial of MRG-106 for cutaneous T-cell lymphoma.
2018 Performance Goals: Corporate goals for 2018 include defining a development plan for MRG-106, advancing MRG-201 for pathological fibrosis, developing the pre-clinical pipeline (including MRG-110 for heart failure), and achieving finance and business development targets.
Risks: The filing references updated risk factors related to the ownership of common stock, incorporated by reference from the preliminary prospectus supplement.
Investor Verification Checklist
- Verify the final audited financial results for the fiscal year ended December 31, 2017, once the offering is completed.
- Confirm the final terms and proceeds of the public offering of up to 7.0 million shares.
- Review the full text of the press release (Exhibit 99.1) regarding Phase 1 data for MRG-106.
- Monitor the achievement of 2018 corporate performance goals tied to executive compensation.
- Check for any material changes to the risk factors disclosed in the preliminary prospectus supplement (Exhibit 99.3).